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SYSTEMATIC REVIEW OF EFFICACY OUTCOMES REPORTED IN 
RANDOMISED CONTROLLED TRIALS OF FIRST-LINE (1L) THERAPIES 
FOR METASTATIC BREAST CANCER (MBC)
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1Complete Medical Group, Glasgow, UK, 2Complete Medical Group, Macclesﬁeld, UK, 3F. 
Hoffmann—La Roche Ltd, Basel, Switzerland
OBJECTIVES: There is currently some debate around the optimal role of overall 
survival (OS) as a gold standard in assessing the beneﬁts of oncology products. The 
objective of this analysis was to provide evidence to inform this discussion from a 
review of the clinical outcomes in 1L mBC trials reported over the last 10 years. 
METHODS: MEDLINE and Cochrane databases were searched to identify ran-
domised controlled trials of treatments for 1L mBC published between January 1998 
and February 2009. Studies in exclusively human epidermal growth factor receptor 
2-positive populations were excluded. RESULTS: Clinical efﬁcacy data were extracted 
from 36 trials. All 36 trials reported response rate (RR), 34 reported a progression-
based end point and 33 reported OS. The most commonly stated primary efﬁcacy end 
points were progression-based; only 6 trials stated OS as the primary end point. 
Improvement in median OS ranged from 0.1 to 7.8 months, improvement in median 
progression-free survival (PFS) ranged from 0.1 to 6.4 months and improvement in 
RR ranged from 0.3% to 28%. Fourteen trials (39%) reported a signiﬁcant progres-
sion-based beneﬁt, 4 of which (36%) reported signiﬁcant median OS. Each of these 
4 trials also reported a signiﬁcant beneﬁt in RR and median PFS. CONCLUSIONS: 
Overall, very few 1L mBC trials have reported a signiﬁcant median OS beneﬁt. Where 
a signiﬁcant OS beneﬁt was reported, a signiﬁcant overall RR and PFS beneﬁt was 
also reported. These ﬁndings appear important in light of the ongoing debate on the 
relevance of currently used clinical end points in mBC trials.
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STATIN USE AND THE RISK OF COLORECTAL CANCER: A 
POPULATION-BASED COHORT STUDY
Ceccarelli M1, Maio V2, Slabaugh SL2, Rabinowitz C2, Diamond JJ2
1Università degli Studi di Firenze, Firenze , Italy, 2Thomas Jefferson University, Philadelphia, 
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OBJECTIVES: Basic scientiﬁc evidence suggests that statins inhibit the growth of 
colon-cancer cell lines, and secondary analyses of some randomized clinical trials 
suggest that they reduce the risk of colorectal cancer. However, evidence from several 
observational studies has been conﬂicting on whether the risk of colorectal cancer is 
reduced in statin users. We sought to assess the association between statin use and 
the rate of colorectal cancer in a large cohort of residents in Emilia-Romagna, Italy. 
METHODS: We conducted a population-based cohort study using the longitudinal 
health care database of Emilia-Romagna, Italy, a region with approximately 4.2 
million inhabitants. This comprehensive database contains information on all health 
care services rendered to the population, including hospital, outpatient pharmacy and 
specialty data. We identiﬁed all initiators of statins; initiators of glaucoma medications 
served as a comparison group. Colorectal cancer cases were identiﬁed by hospital 
discharge data. Multivariable logistic regression analyses were used to adjust for 
confounding. RESULTS: Patient characteristics were similar in both groups, but statin 
initiators (50,534) were prevalently male, were slightly younger, and used hospital 
services more frequently than glaucoma medication initiators (78,361). During a 
maximum of 3 years of follow-up, the incidence rate of colorectal cancer was lower 
in the statin users than in the glaucoma medication users (0.49% vs. 0.79%; Relative 
Risk, 0.69, 95% CI, 0.52 to 0.92). The adjusted odds ratio for statin use compared 
with nonuse was 0.67 (95% CI, 0.57 to 0.79). CONCLUSIONS: The use of statins 
was associated with a 33% relative reduction in the risk of colorectal cancer after 
adjustment for observable risk factors. Because the analysis may not have accounted 
for every potential confounder, further investigation of the overall beneﬁts of statins 
in preventing colorectal cancer is warranted.
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CANCER INCIDENCE IS INFLUENCED BY INSULIN DOSE AND 
METFORMIN IN TYPE 2 DIABETES
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OBJECTIVES: Patients with insulin-treated type 2 diabetes are more likely to be 
diagnosed with cancer than those on metformin. We looked for evidence of a relation-
ship between insulin dose and cancer incidence in type 2 diabetes, and examined the 
effect of concomitant metformin upon this relationship. METHODS: Three treatment 
cohorts: metformin monotherapy, insulin plus metformin, and insulin only, were 
compared in a retrospective analysis of data from UK general practice. Relative insulin 
exposure was determined by the number of insulin prescriptions per year (<7, 7–10, 
10–15, and >15). Cox proportional hazards models were used to adjust for differences 
in baseline characteristics and for differences in insulin exposure using a time-depen-
dent analysis. RESULTS: The adjusted hazard ratios (HRs) for a diagnosis of cancer 
in the four subgroups treated with insulin alone relative to metformin monotherapy, 
were: 1.24 (95% CI 0.90–1.70), 1.40 (1.05–1.87), 1.99 (1.52–2.61), and 2.75 (2.01–
3.75) with increasing exposure to insulin. The corresponding HRs for insulin com-
bined with metformin were 1.01 (0.72–1.40), 1.14 (0.85–1.52), 1.05 (0.76–1.46) and 
1.40 (0.93–2.11). Introduced as a continuous variable, for those with insulin plus 
metformin the HR for prescribed insulin dose in IUs/kg/day was exactly 1.00 (0.76–
1.29; p = 0.9999). For insulin only, the HR for dose expressed in IUs/kg/day was 1.83 
(1.50–2.24; p < 0.0001). CONCLUSIONS: There was a dose-related association 
between insulin exposure and cancer risk in type 2 diabetes. The highest observed 
rates were in those with lower weight and higher levels of prescribed insulin. Co-
administration of metformin was associated with a lower incidence of cancer at all 
levels of insulin exposure.
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OBJECTIVES: To determine the epidemiology of castration-resistant prostate cancer 
(CRPC). METHODS: Primary care data for males aged ≥40 years with a diagnosis of 
prostate cancer (PC) based on the Read classiﬁcation were selected from The Health 
Improvement Network (THIN) between 1998 and 2008. Patients with CRPC were 
deﬁned by a Read code indicative of medical/surgical castration and evidence of 
increasing levels of prostate speciﬁc antigen (PSA) following hormone/androgen 
therapy. Incidence and mortality rates were based on person years at risk. Survival 
was estimated using Cox regression analyses. To compare survival between CRPC and 
non-CRPC, non-CRPC controls were matched by age, year of diagnosis and baseline 
survival. RESULTS: Between 2003/2007, 8,678 patients with PC were identiﬁed. 
Incidence was 22.4 per 10,000 patient years and prevalence was 153.0 per 10,000 
patients. 969 patients (11.2%) progressed to CRPC. Amongst patients with PC the 
prevalence was 1,530 per 10,000 cases. Rate of ﬁrst recorded metastases was 34.4 per 
1,000 patient years for CRPC compared with 24.8 for non-CRPC. Following CRPC 
onset, the mortality rate was 201.2 per 1,000 patient years compared with 86.7 per 
1,000 for non-CRPC. Based on matched data, the hazard ratio for CRPC relative to 
non-CRPC was 2.61 (p < 0.001). Extrapolated to the UK the data from this study 
would predict approximately 220,000 prevalent cases of PC, 27,000 CRPC and 2,600 
CRPC with recorded metastatic spread. Similarly the annual incidence would predict 
approximately 37,000 PC, 8,400 CRPC and 820 CRPC with recorded metastatic 
spread. CONCLUSIONS: The extrapolated prevalence and incidence estimates of PC 
are comparable to other studies in the UK. CRPC status was associated with a signiﬁ-
cantly greater rate of metastases and mortality. Due to the reliance on PSA readings 
in deﬁning CRPC status it is acknowledged that we may underestimate the incidence 
of CRPC.
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BREAST CANCER PATIENTS ARE TWICE AS LIKE TO DEVELOP 
ARTERIAL THROMBOEMBOLIC EVENTS AFTER DIAGNOSIS COMPARED 
TO CANCER-FREE WOMEN
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Penning-van Beest FJA2, Herings RMC2
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OBJECTIVES: To study occurrence of arterial thromboembolic events before and after 
breast cancer (BC) diagnosis compared to cancer-free controls as this information is 
lacking in published literature. METHODS: Women who had a ﬁrst hospitalization 
for BC between 2002 and 2007 were selected from the PHARMO Record Linkage 
System, which includes drug use and hospitalization data of approximately 3 million 
residents in the The Netherlands. BC patients were matched 1:10 by age with cancer-
free women, using the date of diagnosis as the index date for both BC patients and 
their controls. ATEE were deﬁned as a myocardial infarction, ischemic stroke, unstable 
angina and transient ischemic attack requiring hospitalization and were assessed 12 
months before and 12 months after the index date. RESULTS: The analysis included 
11,473 BC patients, with a mean (±SD) age of 59 (±14) years. ATEE before the index 
date were twice as frequent among BC patients compared with cancer-free controls 
(Odds Ratio = 2.0[95%CI:1.6–2.6]), though prevalence was <1% in both groups. The 
incidence of developing ATEE in the 12-month follow-up period was 6.2 per 1000 
person years among patients and 3.8 among controls. BC patients experienced a higher 
risk of ATEE compared with controls (Hazard Ratio = 1.7 [95%CI:1.3–2.2]). This 
risk was attenuated but remained statistically signiﬁcant after adjusting for prior 
cardiovascular or TEE hospitalization and prior antithrombotic or cardiovascular 
drug use (Hazard Ratio = 1.3[95%CI:1.0–1.7]). Independent risk factors for develop-
ing ATEE in 12 months after diagnosis were age (≥65 versus <65 years), prior use of 
antihypertensives or antidiabetic drugs and total hospital stay >10 days during the 
ﬁrst 6 months of follow-up. CONCLUSIONS: In this population-based study, BC 
patients were twice as likely to develop ATEE compared to cancer-free controls, 
although the frequency of events was low. These results emphasize the need for careful 
observation of BC patients after diagnosis.
